ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Milrinone: Drug information

Milrinone: Drug information
(For additional information see "Milrinone: Patient drug information" and see "Milrinone: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Inotrope;
  • Phosphodiesterase-3 Enzyme Inhibitor
Dosing: Adult
Heart failure with reduced ejection fraction

Heart failure with reduced ejection fraction:

Note: Reserve use for decompensated patients with low cardiac output or evidence of end organ hypoperfusion, in combination with standard heart failure therapies as tolerated (ACCF/AHA [Yancy 2013]).

Continuous infusion: IV: Initial: 0.125 mcg/kg/minute; dosing range: 0.125 to 0.75 mcg/kg/minute; titrate based on clinical end point (eg, end organ perfusion). Use the lowest effective dose to minimize adverse effects (eg, arrhythmia, hypotension) (ACCF/AHA [Yancy 2013]).

Note: Loading doses are usually not recommended due to excess risk of hypotension (ACCF/AHA [Yancy 2013]), but if used, the manufacturer labeling suggests 50 mcg/kg over 10 minutes followed by a continuous infusion.

Postoperative inotropic support in heart transplant recipients

Postoperative inotropic support in heart transplant recipients (off-label use):

Continuous infusion: IV: Usual dose range: 0.375 to 0.75 mcg/kg/minute; titrate to the lowest effective dose based on clinical response and hemodynamic end points; wean as tolerated over the first 3 to 5 days following surgery (ISHLT [Costanzo 2010]).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Conservative initial doses should be utilized, as clearance is highly dependent on kidney function. Titrate dose based on clinical response and hemodynamic end points. Monitor closely for adverse effects, such as arrhythmias and hypotension, which may occur more frequently with kidney dysfunction (ACCF/AHA [Yancy 2013]; Charisopoulou 2014; Chong 2018; Cox 2013; Hasei 2008; Majure 2011).

CrCl 10 to 50 mL/minute: Initial: 0.0625 to 0.125 mcg/kg/minute depending on indication and degree of kidney impairment; titrate cautiously, especially with worsening kidney function. Titrating to >0.375 mcg/kg/minute in significant renal impairment is generally not recommended due to likelihood for accumulation (Rodgers 2016; expert opinion).

CrCl <10 mL/minute: Not established; consider alternative therapy (Chong 2018).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Pediatric

(For additional information see "Milrinone: Pediatric drug information")

Hemodynamic support (eg, acute decompensated heart failure, cardiogenic shock, septic shock): Limited data available; optimal dosing not established: Note: Dosing should be individualized and titrated to effect due to interpatient variability in clearance, with or without low cardiac output syndrome or acute kidney injury (Bailey 2004; Garcia Guerra 2013; Gist 2015; Vogt 2014):

Infants, Children, and Adolescents: IV, Intraosseous: Loading dose (optional): 50 mcg/kg administered over 10 to 60 minutes followed by a continuous IV or intraosseous infusion; infusion dose range: 0.25 to 0.75 mcg/kg/minute; titrate dose to effect (PALS [Kleinman 2010]). Due to the risk of hypotension, some centers do not utilize a loading dose (ACCM [Davis 2017]).

Low cardiac output syndrome (LCOS) following CHD corrective surgery, prevention: Limited data available: Infants and Children: IV: Loading dose: 25 or 75 mcg/kg administered over 60 minutes followed by a continuous IV infusion of 0.25 or 0.75 mcg/kg/minute (Hoffman 2003). Dosing based on a double-blind, placebo-controlled trial which randomized 227 postoperative cardiac surgery patients (age range: 2 days to 6.9 years, median: 3 months) at high risk for LCOS to low-dose milrinone (loading dose: 25 mcg/kg, continuous infusion: 0.25 mcg/kg/minute), high-dose milrinone (loading dose: 75 mcg/kg, continuous infusion: 0.75 mcg/kg/minute), and placebo; results showed patients in the high-dose milrinone group had a 64% relative risk reduction for the development of LCOS compared to placebo; the low-dose milrinone group had a statistically insignificant trend toward reducing the development of LCOS (Hoffman 2003).

Dosing: Kidney Impairment: Pediatric

Infants, Children and Adolescents: Specific recommendations for dosing adjustments in pediatric patients are lacking. Milrinone clearance is significantly reduced and other pharmacokinetic parameters (eg volume of distribution) have shown a high degree of interpatient variability in pediatric patients with acute kidney injury; doses should be individualized and titration based upon hemodynamic and clinical response rather than an algorithmic approach based upon dose adjustment for estimated creatinine clearance (Gist 2015, Vogt 2014).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Obesity: Adult

The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.

Class 1, 2, or 3 obesity (BMI ≥30 kg/m2):

Continuous infusion: IV: Use ideal body weight for initial weight-based dosing, then titrate to hemodynamic effect and clinical response (expert opinion). During therapy, clinicians should not change dosing weight from one weight metric to another (ie, actual body weight to/from ideal body weight) (Erstad 2021; expert opinion). Refer to adult dosing for indication-specific doses.

Rationale for recommendations: There is a paucity of studies evaluating the influence of obesity on milrinone dosing or pharmacokinetics. Milrinone has a small Vd; clearance is affected by kidney dysfunction and milrinone is typically titrated to clinical end points (eg, end organ perfusion, cardiac output/index). Adverse effects may be more frequent with higher doses and/or renal dysfunction (expert opinion).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as lactate:

Generic: 200 mcg/mL (100 mL, 200 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL); 50 mg/50 mL (50 mL); 20 mg/100 mL in Dextrose 5% (100 mL); 40 mg/200 mL with Dextrose 5% (200 mL)

Solution, Intravenous, as lactate [preservative free]:

Generic: 200 mcg/mL (100 mL [DSC], 200 mL [DSC]); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL); 50 mg/50 mL (50 mL); 20 mg/100 mL in Dextrose 5% (100 mL); 40 mg/200 mL with Dextrose 5% (200 mL)

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 1 mg/mL (10 mL, 20 mL)

Administration: Adult

IV: For IV use only. Administer loading dose (optional) undiluted slowly over 10 minutes; diluting to a rounded total volume of 10 or 20 mL may simplify the visualization of the injection rate. Infuse maintenance dose via continuous infusion pump.

Administration: Pediatric

IV, Intraosseous:

Loading dose: Administer undiluted or diluted by slow IV push over at least 10 minutes; to minimize hypotension, slower infusion rates up to 60 minutes may also be used (PALS [Kleinman 2010]) or the loading dose may be divided into two or more doses and each dose is administered over 10 minutes if blood pressure remains within an acceptable range (ACCM [Davis 2017]).

Continuous IV or Intraosseous infusion: Administer as a continuous IV infusion with the use of an infusion pump or syringe pump or an intraosseous infusion until IV access can be obtained in pediatric patients (PALS [Kleinman 2010]). Avoid extravasation; administration into a large vein may help prevent the possibility of extravasation; some suggest central-line administration is preferred, especially in neonates; administration into an umbilical arterial catheter is not recommended (Eichenwald 2017).

Usual Infusion Concentrations: Adult

Note: Premixed solutions available

IV infusion: 20 mg in 100 mL (total volume) (concentration: 200 mcg/mL) of D5W

Usual Infusion Concentrations: Pediatric

Note: Premixed solutions available

IV infusion: 200 mcg/mL

Use: Labeled Indications

Heart failure with reduced ejection fraction: Short-term IV therapy for patients with acute decompensated heart failure with reduced ejection fraction in need of inotropic support.

Use: Off-Label: Adult

Postoperative inotropic support for heart transplant recipients

Medication Safety Issues
Sound-alike/look-alike issues:

Primacor may be confused with Primaxin

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Cardiovascular: Ventricular arrhythmia (ventricular ectopy: 9%, nonsustained ventricular tachycardia: 3%, ventricular tachycardia: 1%, ventricular fibrillation: <1%)

1% to 10%:

Cardiovascular: Supraventricular cardiac arrhythmia (4%), hypotension (3%), angina pectoris (≤1%), chest pain (≤1%)

Central nervous system: Headache (3%)

<1%, postmarketing, and/or case reports: Anaphylaxis, atrial fibrillation, bronchospasm, hepatic insufficiency, hypokalemia, injection site reaction, myocardial infarction, skin rash, thrombocytopenia, torsades de pointes, tremor

Contraindications

Hypersensitivity to milrinone or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported. Observe closely for arrhythmias in this very high-risk patient population; sudden cardiac death has been observed. Due to the prolonged half-life as compared to other inotropic agents, ventricular or atrial arrhythmias may persist even after discontinuation of milrinone especially in patients with renal dysfunction (Cox 2013; Leier 1998). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Brozena 2004).

• Hypotension: Hypotension may occur. Monitor blood pressure closely. Hypotension may be prolonged especially in patients with renal dysfunction (Cox 2013; Leier 1998). Vigorous diuresis may contribute to hypotension; cautious administration of fluids may be required to prevent hypotension. Omitting the bolus dose may decrease the risk of hypotension (Baruch 2001; Cuffe 2002). If hypotension occurs, consider dose reduction or temporary discontinuation.

Disease-related concerns:

• Cardiovascular disease: Avoid use in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction; may aggravate outflow tract obstruction in hypertrophic cardiomyopathy with outflow tract obstruction.

• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias.

• Renal impairment: Use with caution in patients with renal impairment; reduction in infusion rate recommended. Hypotension may be prolonged in patients with renal dysfunction (Cox 2013; Leier 1998).

Other warnings/precautions:

• Appropriate use: A facility for immediate treatment of potential cardiac events, including life-threatening ventricular arrhythmias, must be available. Safe and effective use beyond 48 hours (prolonged use) has not been demonstrated. An increased risk of death and hospitalization has been observed with prolonged use in NYHA Class III/IV heart failure patients. Sudden cardiac death has been reported with prolonged use. Continuous electrocardiographic monitoring is recommended.

• Long-term therapy: According to the ACCF/AHA 2013 heart failure guidelines, long-term use of intravenous inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (ACCF/AHA [Yancy 2013]).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Anagrelide: May enhance the adverse/toxic effect of Milrinone. Risk X: Avoid combination

Riociguat: Milrinone may enhance the hypotensive effect of Riociguat. Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension. Risk C: Monitor therapy

Pregnancy Considerations

Adverse events have not been observed in animal reproduction studies; however, increased resorption was reported in some studies.

Breastfeeding Considerations

It is not known if milrinone is present in breast milk. The manufacturer recommends that caution be exercised when administering milrinone to breastfeeding women.

Monitoring Parameters

Platelet count, electrolytes (especially potassium and magnesium) and fluid status, renal function; ECG, blood pressure, heart rate; infusion site

If pulmonary artery catheter is in place, monitor cardiac index, stroke volume, systemic vascular resistance, pulmonary capillary wedge pressure and pulmonary vascular resistance.

Consult individual institutional policies and procedures.

Mechanism of Action

A selective phosphodiesterase inhibitor in cardiac and vascular tissue, resulting in vasodilation and inotropic effects with little chronotropic activity.

Pharmacokinetics

Onset of action: IV: 5 to 15 minutes

Distribution: Vd beta:

Infants (after cardiac surgery): 0.9 ± 0.4 L/kg (Ramamoorthy 1998)

Children (after cardiac surgery): 0.7 ± 0.2 L/kg (Ramamoorthy 1998)

Adults:

After cardiac surgery: 0.3 ± 0.1 L/kg (Ramamoorthy 1998)

Heart failure (with single injection): 0.38 L/kg

Heart failure (with infusion): 0.45 L/kg

Protein binding, plasma: ~70%

Metabolism: Hepatic (minor); majority is not metabolized (Rocci 1987)

Half-life elimination:

Infants (after cardiac surgery): 3.15 ± 2 hours (Ramamoorthy 1998)

Children (after cardiac surgery): 1.86 ± 2 hours (Ramamoorthy 1998)

Adults:

Heart failure: 2.3 to 2.4 hours; renal impairment prolongs half-life (Rocci 1987)

Severe heart failure undergoing continuous venovenous hemofiltration (CVVH): 20.1 ± 3.3 hours (Taniguchi 2000)

Excretion: Urine (83% as unchanged drug; 12% as 0-glucuronide metabolite); active tubular secretion is a major elimination pathway for milrinone (Rocci 1987)

Clearance:

Infants (after cardiac surgery): 3.8 ± 1 mL/kg/minute (Ramamoorthy 1998)

Children (after cardiac surgery): 5.9 ± 2 mL/kg/minute (Ramamoorthy 1998)

Children (with septic shock): 10.6 ± 5.3 mL/kg/minute (Lindsay 1998)

Adults:

After cardiac surgery: 2 ± 0.7 mL/kg/minute (Ramamoorthy 1998)

Heart failure: 2.2 to 2.3 mL/kg/minute

Pricing: US

Solution (Milrinone Lactate in Dextrose Intravenous)

20 mg/100 mL 5% (per mL): $0.18 - $0.40

40 mg/200 mL 5% (per mL): $0.18 - $0.41

Solution (Milrinone Lactate Intravenous)

10 mg/10 mL (per mL): $0.48 - $4.80

20 mg/20 mL (per mL): $0.33 - $4.74

50 mg/50 mL (per mL): $0.42 - $3.72

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Asicord (CZ);
  • Coritrope (ID);
  • Corotrop (AT, CH, CZ, SE);
  • Corotrope (AR, BE, CL, CO, CU, ES, FR, GR, LU, NL, PL, SI, SK, UY, VE);
  • Inovad (ID);
  • Lunan Likang (CN);
  • Milicor (IN);
  • Milricor (AR);
  • Milron (IN, LK);
  • Nefrisol (LK);
  • Primacor (AU, BR, CR, DO, GB, GT, HK, HN, IL, KR, MT, MX, MY, NI, NZ, PA, SV, TH, TW);
  • Unacor (RO)


For country abbreviations used in Lexicomp (show table)
  1. Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003;145(2):324-329. [PubMed 12595851]
  2. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 45, 145.
  3. Bailey JM, Hoffman TM, Wessel DL, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Pharmacokinet Pharmacodyn. 2004;31(1):43-59. [PubMed 15346851]
  4. Barton P, Garcia J, Kouatli A, et al, "Hemodynamic Effects of I.V. Milrinone Lactate in Pediatric Patients With Septic Shock. A Prospective Double-Blinded, Randomized, Placebo-Controlled, Interventional Study," Chest, 1996, 109(5):1302-12. [PubMed 8625683]
  5. Baruch L, Patacsil P, Hameed A, et al, “Pharmacodynamic Effects of Milrinone With and Without a Bolus Loading Infusion,” Am Heart J, 2001, 141(2):266-73. [PubMed 11174341]
  6. Bhat G. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy. ASAIO J. 2006;52(6):677-681. [PubMed 17117058]
  7. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. 2004;23(9):1082-1086. [PubMed 15454175]
  8. Chang AC, Atz AM, Wernovsky G, et al, "Milrinone: Systemic and Pulmonary Hemodynamic Effects in Neonates After Cardiac Surgery," Crit Care Med, 1995, 23(11):1907-14. [PubMed 7587268]
  9. Charisopoulou D, Leaver N, Banner NR. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. Angiology. 2014;65(4):343-349. doi: 10.1177/0003319713485808. [PubMed 23620310]
  10. Chong LYZ, Satya K, Kim B, Berkowitz R. Milrinone dosing and a culture of caution in clinical practice. Cardiol Rev. 2018;26(1):35-42. doi: 10.1097/CRD.0000000000000165. [PubMed 29045285]
  11. Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956. [PubMed 20643330]
  12. Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J Cardiovasc Pharmacol Ther. 2013;18(5):433-438. [PubMed 23695773]
  13. Cuffe MS, Califf RM, Adams KF Jr, et al, “Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial,” JAMA, 2002, 287(12):1541-7. [PubMed 11911756]
  14. Cusick DA, Pfeifer PB, and Quigg RJ, “Effects of Intravenous Milrinone Followed by Titration of High-Dose Vasodilator Therapy on Clinical Outcome and Rehospitalization Rates in Patients With Severe Heart Failure,” Am J Cardiol, 1998, 82(9):1060-5. [PubMed 9817482]
  15. Davis AL, Carcillo JA, Aneja RK, et al. American college of critical care medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2017;45(6):1061-1093. [PubMed 28509730]
  16. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
  17. Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care. 2021;25(1):77. doi:10.1186/s13054-021-03495-8 [PubMed 33622380]
  18. Felker GM, Benza RL, Chandler AB, et al, “Heart Failure Etiology and Response to Milrinone in Decompensated Heart Failure: Results From the OPTIME-CHF Study,” J Am Coll Cardiol, 2003, 41(6):997-1003. [PubMed 12651048]
  19. Garcia Guerra G, Joffe AR, Senthilselvan A, Kutsogiannis DJ, Parshuram CS. Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease. Intensive Care Med. 2013;39(5):951-957. [PubMed 23435950]
  20. Gist KM, Mizuno T, Goldstein SL, Vinks A. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury. Ther Drug Monit. 2015;37(6):792-796. [PubMed 25860636]
  21. Hasei M, Uchiyama A, Nishimura M, Mashimo T, Fujino Y. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease. Acta Anaesthesiol Scand. 2008;52(7):991-996. doi: 10.1111/j.1399-6576.2008.01671.x. [PubMed 18477069]
  22. Hatzizacharias A, Makris T, Krespi P, et al, “Intermittent Milrinone Effect on Long-Term Hemodynamic Profile in Patients With Severe Congestive Heart Failure,” Am Heart J, 1999, 138(2 Pt 1):241-6. [PubMed 10426834]
  23. Heart Failure Society of America, "HFSA 2006 Comprehensive Heart Failure Practice Guideline," J Card Fail, 2006, 12(1):e1-122. [PubMed 16500560]
  24. Hoffman TM, Wernovsky G, Atz AM, et al, "Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease," Circulation, 2003, 107(7):996-1002. [PubMed 12600913]
  25. Hoffman TM, Wernovsky G, Atz AM, et al, "Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) Study," Am Heart J, 2002, 143(1):15-21. [PubMed 11773907]
  26. James AT, Bee C, Corcoran JD, McNamara PJ, Franklin O, El-Khuffash AF. Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. J Perinatol. 2015;35(4):268-273. [PubMed 25429380]
  27. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(suppl 3):S876-S908.
  28. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998;41(3):207-224. [PubMed 9872607]
  29. Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr. 1998;132(2)329-334. [PubMed 9506650]
  30. MacDonald MG, Seshia MMK, eds. Avery's Neontatology - Pathophysiology and Management of the Newborn. 7th ed. Philadelphia, PA: Wolters Kluwer; 2016.
  31. Majure DT, Teerlink JR. Update on the management of acute decompensated heart failure [published online October 6, 2011]. Curr Treat Options Cardiovasc Med. doi: 10.1007/s11936-011-0149-2. [PubMed 21976129]
  32. McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21(2):217-222. [PubMed 16769471]
  33. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med. 2013;14(1):74-84. [PubMed 23132395]
  34. Milrinone lactate [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; July 2020.
  35. Milrinone Lactate in Dextrose Injection (milrinone lactate in dextrose) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.
  36. Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508. [PubMed 25147175]
  37. Pamboukian SV, Carere RG, Webb JG, et al, “The Use of Milrinone in Pretransplant Assessment of Patients With Congestive Heart Failure and Pulmonary Hypertension,” J Heart Lung Transplant, 1999, 18(4):367-71. [PubMed 10226902]
  38. Paradisis M, Evans N, Kluckow M, et al, "Pilot Study of Milrinone for Low Systemic Blood Flow in Very Preterm Infants," J Pediatr, 2006, 148(3):306-13. [PubMed 16615956]
  39. Peberdy MA, Callaway CW, Neumar, RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(suppl 3):S768-S786.
  40. Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” Am J Health Syst Pharm, 2011, 68(22):2176-82. [PubMed 22058104]
  41. Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg. 1998;86(2):283-289. [PubMed 9459233]
  42. Rocci ML Jr, Wilson H. The pharmacokinetics and pharmacodynamics of newer inotropic agents. Clin Pharmacokinet. 1987;13(2):91-109. [PubMed 3304772]
  43. Rodgers JE, Reed BN. Acute Decompensated Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, eds. Pharmacotherapy: A Pathophysiologic Approach, 10th ed. New York, NY: McGraw-Hill; 2016.
  44. Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in Hosp Pharm. 2007;42:84-85]. Hosp Pharm. 2006;41(11):1102-1106.
  45. Stevenson LW, “Inotropic Therapy for Heart Failure,” N Engl J Med, 1998, 339(25):1848-50. [PubMed 9854124]
  46. Taniguchi T, Shibata K, Saito S, et al, “Pharmacokinetics of Milrinone in Patients With Congestive Heart Failure During Continuous Venovenous Hemofiltration,” Intensive Care Med, 2000, 26(8):1089-93. [PubMed 11030165]
  47. Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant. 2004;23(4):466-472. [PubMed 15063407]
  48. van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525. [PubMed 28923988]
  49. Vogt W. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model. Clin Pharmacokinet. 2014;53(1):51-72. [PubMed 23839530]
  50. Wilson TD, Forde MD, Crain AVR, Dombrowski LJ, Joyce MA. Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections. Am J Hosp Pharm. 1986;43(9):2218-2220. [PubMed 3766576]
  51. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327. [PubMed 23741058]
  52. 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S640-S933.
Topic 9652 Version 255.0